id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2000-D-0187-0003,FDA,FDA-2000-D-0187,"Draft Guidance for Industry Recommedations for Donor Questioning, Deferral, Reentry, and Product Management to Reduce Risk of Transfusion-Transmitted Malaria",Other,Guidance,2012-07-06T04:00:00Z,2012,7,2012-07-06T04:00:00Z,2012-09-05T03:59:59Z,2024-11-07T22:45:32Z,,1,0,090000648107d6f4
FDA-2000-D-0187-0002,FDA,FDA-2000-D-0187,"Draft Guidance for Industry:Recommedations for Donor Questioning, Deferral, Reentry, and Product Management to Reduce Risk of Transfusion-Transmitted Malaria; Availability",Notice,Notice of Data Availability,2012-07-06T04:00:00Z,2012,7,2012-07-06T04:00:00Z,2012-09-05T03:59:59Z,2012-09-07T02:01:07Z,2012-16528,0,0,090000648107d34d